

BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019

March 18, 2019

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 18, 2019-- [BioTime, Inc.](#) (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 20th, 2019 at 2:45pm Eastern Time at the Westin New York Grand Central in the Track 2 Room in New York, NY.

Interested parties can access a live audio webcast on the [Events and Presentations](#) section of BioTime's website and an archived presentation will be available for 30 days. Interested parties may follow @OppenheimerCo on Twitter and use #OPCOHealthcare for the latest conference updates.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. BioTime's programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform BioTime develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury, or administered as a means of helping the body mount an effective immune response to cancer. BioTime's clinical assets include (i) OpRegen[®], a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.biotimeinc.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190318005113/en/>

Source: BioTime, Inc.

BioTime Inc. IR

Ioana C. Hone
(ir@biotimeinc.com)
(510) 871-4188

Solebury Trout IR

Gitanjali Jain Ogawa
(Gogawa@troutgroup.com)
(646) 378-2949